You are here: Home: Meet The Professors Vol. 4 Issue 3 : Faculty Disclosures

Faculty Affiliations

	Joanne L Blum, MD, PhD Director, Hereditary Cancer Risk Program and Research Site Leader Baylor-Charles A Sammons Cancer Center Dallas, Texas		Julie R Gralow, MD Associate Professor Medical Oncology University of Washington and Fred Hutchinson Cancer Research Center Seattle, Washington
	Richard M Elledge, MD Medical Director Breast Care Center Associate Professor of Medicine Baylor College of Medicine Houston, Texas		Debu Tripathy, MD Professor of Internal Medicine Director, Komen UT Southwestern Breast Cancer Research Program University of Texas Southwestern Medical Center Dallas, Texas

Medical Oncologist Community Panel

Alan B Astrow, MD New York, New York Elizabeth E Campbell, MD Raleigh, North Carolina Patricia A De Fusco, MD Hartford, Connecticut

David M Dresdner, MD St Petersburg, Florida Carolyn B Hendricks, MD Bethesda, Maryland Atif M Hussein, MD Hollywood, Florida

Michael A Schwartz, MD Miami Beach, Florida Leonard J Seigel, MD Fort Lauderdale, Florida Richard S Zelkowitz, MD Norwalk, Connecticut

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Blum — Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Abraxis Oncology, Roche Laboratories Inc. Dr Elledge — Consulting Fees: AstraZeneca Pharmaceuticals LP. Dr Gralow — Consulting Fees: Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Novartis Pharmaceuticals, Roche Laboratories Inc; Fees for Non-CME Services Received Directly from Commercial Interest or their Agents: Genentech BioOncology, Roche Laboratories Inc. Dr Tripathy — Consulting Fees: Genentech BioOncology, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Roche Laboratories Inc.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.